Urinary excretion of free toluenediamines in a patient with polyurethane-covered breast implants.

We report the detection of free 2,4-toluenediamine in urine of a patient implanted with polyurethane-covered breast implants. Samples were collected on several dates, ranging from 21 days to seven months after the insertion of the implants, and these samples all showed the presence of free 2,4-toluenediamine at a concentration of about 1 micrograms/L. The chemical was not found in a urine sample collected before implantation. This finding is important for risk assessment of cancer in patients with this type of breast implant because the chemical is a suspected carcinogen. Free 2,6-toluenediamine, an isomer, was also found in all samples from this patient.

Drug analysis at the 1988 Olympic Winter Games in Calgary.

A comprehensive drug testing program was carried out during the 16 days of the 1988 Olympic Winter Games in Calgary, Canada. State-of-the-art technology was applied, involving high-resolution gas chromatography, high-performance liquid chromatography, gas chromatography/mass spectrometry, fluorescence polarization immunoassay, and radioimmunoassay. Samples from selected athletes were screened for five drug classes: stimulants, narcotic analgesics, anabolic steroids, beta-blockers, and diuretics. In addition, samples were also screened for local anesthetics, corticosteroids, beta-human choriogonadotropin, and cannabinoids. During the 16-day event, 428 urine samples were processed and 3090 screening procedures performed. We describe the methods for analysis at the Olympic Games and present the results.

Detection of toluenediamines in the urine of a patient with polyurethane-covered breast implants.

Breast prostheses are implanted for augmentation or during reconstructive surgery. One of the more commonly used prostheses is the polyurethane-sponge-covered silicone gel implant. Some clinicians are concerned about the safety of this product because the polyurethane foam disintegrates in vivo, and its subsequent fate is not known. Polyurethane is a polymer formed by reacting diisocyanates and polyols. This study indicates that the polymer sponge breaks down into its reactive monomers, 2,4- and 2,6-toluenediisocyanate, which are converted into their corresponding diamines. We present evidence of the excretion of the diamine metabolites in the urine of a patient implanted with polyurethane-covered prostheses.

Analysis of bumetanide in human urine by high-performance liquid chromatography with fluorescence detection and gas chromatography/mass spectrometry.

Bumetanide is a potent diuretic. Its concentration in urine after therapeutic doses is in the low ng/mL range. A procedure using reversed-phase HPLC with fluorescence detection is described. Using this procedure, the authors have been able to measure bumetanide in a urine sample at 10 ng/mL with a signal-to-noise ratio of 7. Therefore, the detection limit is lower than this concentration. Confirmation is by a GC/MS procedure after methylating the diuretic. Derivatization is by extractive alkylation with tetrabutylammonium hydrogen sulfate as the phase transfer reagent and iodomethane as the methylating agent.

Urinary excretion of furazabol metabolite.

Furazabol, a newer anabolic steroid, is metabolized into 16-hydroxyfurazabol and excreted in urine. The presence of this compound in urine can be monitored with a GC/MS procedure. It can be incorporated into the general dope testing protocol for anabolic steroids.